Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Skye Bioscience to Present at Upcoming Investment Conferences tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Promising Minimum Inhibitory Concentration (MIC) activity in Phase I/II trial for urinary tract infections (UTI) and urosepsis with an increase in dosage expected to begin in the next several weeksExpansion of Phase I/II trial for diabetic foot infections (DFI) with efficacy achieved and now moving towards the initiation of a Phase III registrational trial in Indonesia scheduled to commence in Q3 2024RECCE® 327 (R327) shown to be effective against more than 300 strains of bacterial pathogens dur
SOUTH SAN FRANCISCO, Calif., April 09, 2024 Aligos Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in.